Literature DB >> 8330823

[Long-term tolerance of flupirtine. Open multicenter study over one year].

W M Herrmann1, R Hiersemenzel, M Aigner, M Lobisch, H Riethmüller-Winzen, I Michel.   

Abstract

METHOD: To answer the question as to whether the analgesic flupirtine is suitable for long-term treatment of chronic pain, its side effects and efficacy were investigated over a 12-month treatment period. A total of 191 patients with chronic pain of degenerative and/or inflammatory musculoskeletal diseases were admitted to the open, uncontrolled multicenter study. This was followed by a single-blind placebo follow-up period of two weeks aimed at detecting withdrawal phenomena as a sign of a possible addictive potential of flupirtine.
RESULTS: On the basis of patient and investigator documentation, laboratory studies and clinical examinations, flupirtine was found to be both well tolerated and effective. No signs of tolerance, addiction or relevant interactions were observed. The side effect profile differed from that of the opioids or prostaglandin synthesis inhibitors (NSAIDs).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330823

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  5 in total

1.  Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years.

Authors:  Martin C Michel; Piotr Radziszewski; Christian Falconer; Daniela Marschall-Kehrel; Koenraad Blot
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia.

Authors:  A Richter; S E Sander; C Rundfeldt
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 3.  Flupirtine in pain management: pharmacological properties and clinical use.

Authors:  Jacques Devulder
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

4.  Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

Authors:  Muriel B Sättler; Sarah K Williams; Clemens Neusch; Markus Otto; Jens R Pehlke; Mathias Bähr; Ricarda Diem
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

5.  Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Authors:  Jan Dörr; Klaus-Dieter Wernecke; Jens Würfel; Judith Bellmann-Strobl; Volker Siffrin; Muriel B Sättler; Mikael Simons; Andreas Linsa; Hayrettin Tumani; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-09       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.